M
Moody D. Wharam
Researcher at Johns Hopkins University
Publications - 186
Citations - 11037
Moody D. Wharam is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Rhabdomyosarcoma & Radiation therapy. The author has an hindex of 57, co-authored 186 publications receiving 10515 citations. Previous affiliations of Moody D. Wharam include University of Minnesota & Cincinnati Children's Hospital Medical Center.
Papers
More filters
Journal ArticleDOI
Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease
William M. Crist,James R. Anderson,Jane L. Meza,Chris Fryer,R. Beverly Raney,Frederick B. Ruymann,John C. Breneman,Stephen J. Qualman,Eugene S. Wiener,Moody D. Wharam,Thom L. Lobe,Bruce Webber,Harold M. Maurer,Sarah S. Donaldson +13 more
TL;DR: VAC and VAI or VIE with surgery (with or without RT), are equally effective for patients with local or regional rhabdomyosarcoma and are more effective for embryonal tumors than therapies used previously.
Journal ArticleDOI
The intergroup rhabdomyosarcoma study-II
Harold M. Maurer,Harold M. Maurer,Edmund A. Gehan,Mohan Beltangady,William Crist,Paul S. Dickman,Sarah S. Donaldson,Christopher Fryer,Denman Hammond,Daniel M. Hays,Janice Herrmann,Ruth Heyn,Pat Morris Jones,Walter Lawrence,William Newton,Jorge Ortega,Abdelsalam H. Ragab,R. Beverly Raney,Frederick B. Ruymann,Edward Soule,Melvin Tefft,Bruce Webber,Eugene Wiener,Moody D. Wharam,Teresa J. Vietti +24 more
TL;DR: The aim of the IRS was to improve the survival and treatment of children with rhabdomyosarcoma and to establish anaesthetised children with RMS who responded well to chemotherapy.
Journal ArticleDOI
Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IV
John C. Breneman,Elizabeth R. Lyden,Alberto S. Pappo,Michael P. Link,James R. Anderson,David M. Parham,Stephen J. Qualman,Moody D. Wharam,Sarah S. Donaldson,Harold M. Maurer,William H. Meyer,K. Scott Baker,Charles N. Paidas,William M. Crist +13 more
TL;DR: Children with group IV RMS treated on the IRS-IV study had improved OS and FFS if they had two or fewer metastatic sites and embryonal histology, and these patients might not be appropriate candidates for regimens that include experimental agents with substantial toxicities or unproven antitumor activity.
Journal ArticleDOI
Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study.
Michael D. Amylon,J J Shuster,Jeanette Pullen,Costan W. Berard,Michael P. Link,Moody D. Wharam,J A Katz,Alice L. Yu,Joseph Laver,Yaddanapudi Ravindranath,Joanne Kurtzberg,S Desai,Bruce M. Camitta,Sharon B. Murphy +13 more
TL;DR: It is concluded that when added to a backbone of effective rotating agents, repeated doses of asparaginase during early treatment improve the outcome for patients with T cell leukemia and advanced stage lymphoblastic lymphoma.
Journal ArticleDOI
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Carola A.S. Arndt,Julie A. Stoner,Douglas S. Hawkins,David A. Rodeberg,Andrea Hayes-Jordan,Charles N. Paidas,David M. Parham,Lisa A. Teot,Moody D. Wharam,John C. Breneman,Sarah S. Donaldson,James R. Anderson,William H. Meyer +12 more
TL;DR: For intermediate-risk RMS, VAC/VTC does not significantly improve FFS compared with VAC, and the frequency of second malignancies was similar between the two treatment groups.